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Abstract
Background: The RNA binding protein, DEAD END (DND1), is essential for maintaining viable germ cells in
vertebrates. It is also a testicular germ cell tumor susceptibility factor in mice. DND1 has been shown to interact
with the 3’-untranslated region (3’-UTR) of mRNAs such as P27 and LATS2. Binding of DND1 to the 3’-UTRs of these
transcripts blocks the inhibitory function of microRNAs (miRNA) from these transcripts and in this way DND1 helps
maintain P27 and LATS2 protein expression. We found that DND1 is also expressed in embryonic stem (ES) cells.
Because ES cells share similar gene expression patterns as germ cells, we utilized ES cells to identify additional
candidate mRNAs that associate with DND1.
Results: ES cells are readily amenable to genetic modification and easier to culture in vitro compared to germ
cells. Therefore, for the purpose of our study, we made a genetically modified, stable, human embryonic stem (hES)
cell line that expresses hemagluttinin (HA)-tagged DND1 in a doxycycline (dox) regulatable manner. This line
expresses modest levels of HA-DND1 and serves as a good system to study DND1 function in vitro. We used this
stable cell line to identify the transcripts that physically interact with DND1. By performing ribonucleoprotein
immunoprecipitation (RIP) followed by RT-PCR, we identified that transcripts encoding pluripotency factors (OCT4,
SOX2, NANOG, LIN28), cell cycle regulators (TP53, LATS2) and apoptotic factors (BCLX, BAX) are specifically associated
with the HA-DND1 ribonucleoprotein complex. Surprisingly, in many cases, bioinformatics analysis of the pulled-
down transcripts did not reveal the presence of known DND1 interacting motifs.
Conclusions: Our results indicate that the inducible ES cell line system serves as a suitable in vitro system to
identify the mRNA targets of DND1. The RIP-RT results hint at the broad spectrum of mRNA targets that interact
with DND1 in ES cells. Based on what is known about DND1 function, our results suggest that DND1 may impose
another level of translational regulation to modulate expression of critical factors in ES cells.
Background
Inactivation of the Dnd1 gene results in sterility in verte-
brates as well as causes development of testicular germ
cell tumors in mice [1,2]. Dnd1 function is essential to
maintain viable germ cells in vertebrates [3,4]. Mice with
inactivated Dnd1 show progressive reduction in germ cell
numbers starting around embryonic day (E) 8 and are
therefore rendered sterile at birth. In addition, when
inactivation of Dnd1 occurs in 129 strain mouse back-
ground, these mice have a very high incidence of
testicular germ cell tumors [5-7]. Thus, on the 129 back-
ground, some germ cells escape death to undergo cancer-
ous transformation. The transformed germ cells
eventually differentiate randomly into myriad cell types
that constitute the teratomas or teratocarcinomas in the
testes. The testicular germ cell tumors in mice resemble
human pediatric testicular type I germ cell tumors [8,9].
DND1 has canonical RNA recognition motifs (RRM)
[1,10,11]. Mutations engineered in the RRM prevent
interaction of DND1 with mRNAs and have also been
reported to prevent nucleo-cytoplasmic translocation of
zebrafish DND1 [10]. In addition, a disease associated
nucleotide polymorphism in the highly conserved RRM
of DND1 was detected in a human patient with germ cell
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interacts with the 3’-untranslated region (UTR) of
mRNAs such as that of the cell cycle inhibitor, P27
(p27
Kip1, CDKN1B) and cell cycle regulator and tumor
suppressor, LATS2 (large tumor suppressor, homolog 2
of Drosophila - a serine/threonine-protein kinase)
[11,13]. DND1 interacts with U-rich sequences found in
the 3’-UTR of P27.I nt h ec a s eo fP27, interaction of
DND1 hindered miR-221 access to P27 3’-UTR. This led
to increased expression levels of P27. Although DND1
inhibits mir-372 and 373 from LATS2 mRNA, the
DND1-binding sequences on the 3’-UTR of LATS2 have
not been identified. DND1 was also shown to interact
with the U-rich sequences on zebrafish Nanos1 and
TDRD7 mRNAs.
The exact mechanism as to how DND1 prevents
miRNA-mediated translation repression is unclear. In the
case of P27, Nanos1 and TDRD7, the U-rich sequences are
found adjacent to miRNA binding sites [10,11]. This sug-
gests that DND1 may bind to mRNA to physically displace
the miRNAs and miRISC (miRNA-induced silencing com-
plexes). An alternate possibility is that DND1 may bind
mRNA and sequester it away from miRNA access.
In the mouse, DND1 is detected in the early embryo
[2,14] and then becomes enriched in primordial germ cells
(PGCs) after ~ E8 [3,15]. We also detected DND1 expres-
sion in mouse (mES) [14] and human embryonic stem
cells (hES). PGCs and ES cells share gene expression pat-
terns, markers and miRNAs in common [16]. For example,
both PGCs and ES cells express cellular markers such as
OCT4, VASA, NANOG and FRAGILIS. They express
similar miRNA families such as miR 209-295, miR 302-
367 and miR 17-92 [17-20] and express critical pluripo-
tency factors such as OCT4, SOX2 and NANOG [3,21-24].
Indeed, there is speculation that ES cells may be derived
from germ cells of the early embryo [25]. Because ES cells
express DND1, it is expected that they also normally
express the mRNAs and miRNAs whose activity is modu-
lated by DND1. Moreover, ES cells are easily cultured in
vitro and are more experimentally amenable compared to
germ cells. Therefore, ES cells should serve as a good sys-
tem to study DND1 function. We therefore sought to
determine the mRNA targets of DND1 in hES cells. We
expect that there are shared sets of mRNA targets in
PGCs and ES cells and knowledge of the nature of the
transcripts that associate with DND1 will illuminate the
function of DND1 in pluripotent cell types such as in ES
and germ cells.
Methods
Generation of stable hES/HA-DND1 cell lines
The hES cell lines H1 (WA01) and H9 (WA09) (WiCell
Research Institute, Madison, WI) [26] were cultured on
mitotically inactivated mouse embryonic fibroblasts or
under feeder free conditions on Matrigel (BD Bio-
sciences). H9 (WA09) hES lines were genetically modi-
fied to stably express HA-tagged human DND1 in an
inducible manner. Two recombinant lentiviral constructs
were introduced into H9 cells. Introduction of the first
lentivirus, which expresses transactivator (rtTA) from a
constitutive Ubiquitin promoter (UbC), generated H9-
rtTA cells [27]. The second virus encodes the inducible
target locus (DND1 with HA-tag cloned at 3’ end) down-
stream of the doxycycline-responsive promoter (sgTRE)
[28], and bears an IRES-GFP reporter (Figure 1c). The
cell line (hES/HA-DND1 cells) containing both viruses
was derived by two rounds of transient and low dose
doxycycline induction (50 ng/uL, overnight), followed by
flow cytometry for GFP+ cells.
Thus, the derived hES/HA-DND1 cells use the tetra-
cycline on (Tet-On) system, in which treatment of cells
with doxycycline (dox) causes dox-activated transactiva-
tor to interact with the sgTRE element to turn on
expression of HA-DND1.
FACS analysis
Dual labeling using anti-SSEA-4 and anti-OCT4 antibo-
dies was performed on hES/HA-DND1 cell lines to deter-
mine the percent of undifferentiated cells in the
population. hES/HA-DND1 cells ranged from 50% to
77% positive (double-labeled) for the markers OCT4 and
SSEA-4. These hES/HA-DND1 cells were subsequently
passaged and treated with dox prior to performing RIP
experiments.
Induction of HA-DND1 with increasing concentrations of
doxycycline
hES/HA-DND1 cells, grown on Matrigel in 6-well
plates, were treated with increasing concentrations,
100 - 500 ng/mL, of doxycycline (dox) for 24 h. The
cells were lysed and used for immunoblotting.
Immunoblotting with rabbit anti-DND1 antibody, anti-
HA antibody and anti-GAPDH was performed as
described [14]. Densitometric analysis was performed to
quantitate the band intensities.
Ribonucleoprotein immunoprecipitation (RIP or RNP
immunoprecipitation) assay
RIP was performed essentially as described in [29]. 3 inde-
pendent RIP experiments followed by RT-PCR were per-
formed and one representative result is shown (Figures 2
and 3). hES/HA-DND1 cells, grown on Matrigel, were
treated with dox (500 ng/mL) for 24 h. Control ES cells
were untreated. The cells were subsequently lysed and cell
extracts were made with mild lysis buffers to minimize
exchange of mRNAs between proteins. The lysates (also
referred to as mRNP extracts) were incubated with anti-
HA antibody (Sigma) linked to agarose beads. Excess
tRNA (250 ug yeast tRNA) was included to block spurious
interaction of RNAs with HA-DND1. As another control,
we incubated mRNP extracts from dox treated cells with
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Page 2 of 10Figure 1 DND1 expression in hES cells.( a) Immunoblotting using anti-DND1 antibody of MEF, hES line H9, mouse testes (T) and spleen (S)
(10 μg protein/lane). Control (C) is 293T cells transfected with HA-DND1 encoding expression vector. (bottom) Blot reprobed with anti-GAPDH.
(b) RT-PCR to amplify DND1 in human testes (T), hES cells H1, H9, and MEFs. (+) lanes had superscript; (-) had no superscript during RT. (bottom)
RT-PCR for HPRT.( c) . The first virus expresses rtTA that binds dox. The second virus carries dox-responsive promoter (sgTRE) that drives HA-
DND1 expression. Dox also induces GFP expression, which allows identification of cells carrying both constructs. att (sites for recombinational
cloning); LTR and ΔLTR (long terminal repeats); IRES (internal ribosome entry site). (d) FACS analysis indicates hES/HA-DND1 cells maintain high
expression (77% +ve) of OCT4 and SSEA-4 (quadrant Q2, top right). (e) hES/HA-DND1 cells induced to express HA-DND1 upon dox treatment
(100 to 1000 ng/mL) for 24 h. Immunoblotting using anti-HA antibody (top panel), anti-DND1 antibody (middle panel) and anti-GAPDH antibody
(bottom panel) (20 μg hES/HA-DND1 lysates/lane). Relative HA-DND1 levels (fold HA) range from 1.6 - 3.7 fold with increasing dox. (Relative HA-
DND1 of each lane is ratio of HA-DND1/GAPDH). The level of endogenous DND1 (DND1/GAPDH) in hES/HA-DND1 cells treated with 0 to 1000
ng/mL dox was 1.2, 0.9, 1.1, 1.1 and 0.7, respectively. The level of induced HA-DND1 to endogenous DND1 levels (HA/endog) was estimated to
be 1.7 to 5.4-fold, with increasing dox.
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Page 3 of 10anti-FLAG antibody linked to beads (Sigma). The anti-
FLAG antibody used was the same IgG1 isotype as the
anti-HA antibody.
The beads (linked to anti-HA antibody and now asso-
ciated with HA-DND1 and RNAs) were pelleted by cen-
trifugation, extensively washed, treated with proteinase
K and the RNA was eluted off. The extracted RNA was
used to prepare cDNA. RNA concentrations were mea-
sured using NanoDrop spectrophotometer (Thermo
Scientific) and equivalent amounts were used to prepare
cDNA. The ‘High capacity RNA-to-cDNA Master Mix
with NO RT control’ kit (applied biosystems) was used
for cDNA preparation. cDNA was also prepared from
the other fractions: mRNP lysates, input(I) and superna-
tant (S) (Figure 2b). Aliquots from these fractions were
saved during the RIP procedure.
PCR was performed to analyze the RIP, I and S fractions
for transcripts encoding P27, HPRT, etc. The primers for
Figure 2 The RIP-RT procedure.( a) Outline of RIP-RT procedure. hES/HA-DND1 cells were treated with and without dox. Anti-HA antibody was
used to pull-down HA-DND1 together with associated mRNA. The mRNA was eluted and RT-PCR used to amplify and detect P27.( b) Details of
the RIP procedure as described in [29]. hES/HA-DND1 cells were used to prepare lysates (mRNP lysates). A fraction of the lysate was used as
input (I) for immunoprecipitation (IP) using anti-HA antibody linked to beads. After an overnight incubation, the input was centrifuged. The
supernatant (S) was removed. RNA was extracted from the beads (RIP fraction), I and S fractions and used for RT-PCR. (c) PCR for P27 and HPRT
on the input (I), supernatant (S) and immunoprecipitation (RIP) fractions. ES cells treated with (+) and without (-) dox were used. Each fraction of
the ES cells with and without dox treatment was used to generate cDNA. The RT: + represents presence of Reverse Transcriptase and the RT: -
represents no Reverse Transcriptase (control) during cDNA synthesis. (d) P27 levels in input fraction of untreated (dox-) and treated (dox+) cells
when higher PCR cycle numbers (35 cycles) are used. (e) (top) Immunoblotting for HA-DND1 in the mRNP lysates, input and supernatant fraction
of ES cells treated with (+) or without (-) dox. Control (C) was 293T cells transfected with HA-DND1 encoding expression vector. (bottom) Blots
were reprobed with GAPDH. Relative HA-DND1 levels (HA-DND1/GAPDH ratios) in the fractions are indicated at the bottom in blue.
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Page 4 of 10Figure 3 (a) Outline of RIP-RT and controls. hES/HA-DND1 cells were treated with dox (+DOX) or not treated with dox (-DOX). The cells were
used to make mRNP lysates and the input fraction was incubated with anti-HA antibody or as control, anti-FLAG antibody for RIP. Excess tRNA
was added to the input. RNA extracted from the RIP fraction was used for RT-PCR. (b) Defining the pluripotency factors which are targets of
DND1. Anti-HA antibody (a-H) or anti-FLAG (a-F) was used for RIP. After RIP, RT-PCR was performed on equal amounts of cDNA from I, S and RIP
fractions. RT+ indicates presence of Reverse Transcriptase during cDNA preparation. RT- are control lanes with no Reverse Transcriptase. Specific
pull down of OCT4, SOX2 and NANOG by anti-HA antibody is observed in lane 13. The PCR cycle number used to detect each transcript is
described in Methods. (c) Transcripts encoding pluripotency factors and cell cycle regulators targets are targets of DND1. RT-PCR of the S fraction
was not performed on these samples. Specific pull down of LIN28, TP53 and LATS2 by anti-HA antibody is observed in lane 7. (d) Pro-apototic
factor BAX and anti-apoptotic factor BCLX are specifically pulled down with HA-DND1 during RIP using anti-HA antibodies (lane 7).
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Page 5 of 10RT-PCR were as follows [30-34]: P27-F ttaaaaatacatatcgct-
gacttc, P27-R cttcataccccgctccac, OCT4-F gacaacaat-
gaaaatcttcaggaga, OCT4-R ctggcgccggttacagaacca, SOX2-F
cccccctgtggttacctcttc, SOX2-R ttctcccccctccagttcg,
LATS2-F gcgacctctgggatgatgtg, LATS2-R ttggagtccccac-
cagtgaa, NANOG-F atgcctgtgatttgtgggcc, NANOG-R
gccagttgtttttctgccac, MYC-F cccgcgacgatgcccctcaac, MYC-
R agaagccgctccacatacagtcct, LIN28-F acgtgcgcatggggttcg,
LIN28-R tgggccttcagcggacat, KLF4-F aggtggcgggctgatggg-
caagtt, KLF4-R gaagcggcagggcagggtgacagt, TP53-F ccccc
tcctggcccctgtcatctt, TP53-R ccgggcgggggtgtggaatcaac,
BCLX-F catggcagcagtaaagcaag, BCLX-R gcattgttcccatagag
ttcc, BAX-F ggcccaccagctctgagcagatc; BAX-R gacaacccg
gccccagttgaagtt, HPRT-F gttgagagatcatctccacc, HPRT-R
agctatgatgaaccaggtta.
The PCR cycle for each transcript was adjusted
depending on the nature of the primer and abundance
of the transcript, as determined in preliminary experi-
ments (data not shown). PCR cycles for each transcript
w a sa sf o l l o w s :P27 ( 3 0o r3 5c y c l e s ) ,HPRT1 (35 or 24
cycles), OCT4, SOX2 and NANOG (26 cycles), LIN28,
KLF4, MYC, TP53, LATS2, BAX and BCLX (35 cycles).
The expected sizes of the RT-PCR products are: 216 bp
for OCT4, 232 bp for SOX2, 403 bp for NANOG, 394
bp for LIN28, 424 bp for MYC, 347 bp for KLF4, 126 bp
for LATS2,1 9 9b pf o rTP53, 351 bp xL product from
BCLX and 299 bp for BAX.
DND1 interacting sequences
We examined full-length transcripts for the known human
P27 DND1 interacting sequence [11] TTTTTCCTTATTT
or TTTTTACCTTTT; Nos1 DND1 interacting sequence
TGTTTGATTTT or TTTTATTTT and TDRD7 DND1
interacting sequence TTGATTTT. In cases where multi-
ple transcripts are present, all known transcripts were
examined for the presence of any of the known DND1
interacting sequences.
Results
DND1 expression in human ES cells
We previously detected DND1 expression in G4 mouse
ES cells [14]. Using immunoblotting and RT-PCR tech-
niques, we were also able to detect DND1 expression in
human embryonic stem cells (hES), H1 (WA01) and H9
(WA09) (Figure 1a and 1b). However, DND1 is not
detected in mouse embryo fibroblast (MEF) cells, the
feeder cells on which the hES cells grow. In the case of
MEFs, bands are observed in both superscript (-) and
superscript (+) lanes (Figure 1b). These likely are non-
specific bands and indicate no specific DND1 expression
in MEFs, as was also previously shown [14].
Doxycycline-inducible expression of HA-DND1 in hES cells
We established lentiviral modified hES lines that express
HA-tagged human DND1 (hES/HA-DND1) in an
inducible manner. The hES/HA-DND1 cell line uses the
tetracycline on (Tet-On) system in which doxycycline
turns on the expression of HA-DND1 [35,36] (Figure 1c).
T h eh E S / H A - D N D 1c e l ll i n es h o w e dam o d e s td o s e -
dependent increase of HA-DND1 levels (1.6 to 3.7 - fold
increase of HA-DND1 levels) upon treatment with
increasing concentrations of dox for 24 h (Figure 1e, top
panel). We also determined the levels of endogenous
DND1 expression using anti-DND1 antibody (Figure 1e,
middle panel). The level of endogenous DND1 in hES/
HA-DND1 cells treated with increasing dox was fairly
similar (band intensities were 1.2, 0.9, 1.1, 1.1 and 0.7 with
0 to 1000 ng/mL dox, respectively). Comparing the levels
of induced HA-DND1 to endogenous DND1 (HA/endog,
Figure 1e), we estimate that HA-DND1 levels range from
about a 2 to 6-fold increase compared to endogenous
DND1. For subsequent RIP experiments, we treated hES/
HA-DND1 cells with 500 ng/mL dox for 24 h which
induces a 2.8-fold higher level of HA-DND1 compared to
endogenous DND1 levels.
HA-DND1 associated P27 mRNA
First, we performed RIP [29,37,38] to test whether HA-
tagged DND1, induced to be expressed in the hES/HA-
DND1 cell line, can pull down P27 mRNA. This is because
it has been previously shown that DND1 binds to the
3’-UTR of P27 mRNA [11].
hES/HA-DND1 cells were treated with dox (500 ng/mL
for 24 h) whereas control cells were untreated. The cells
were subsequently lysed to make the cell extracts that
were used to perform RIP as described in Methods [29]
and outlined in Figure 2.
We used RT-PCR to analyze the RIP, I and S fractions
for P27. cDNA was made using equal amounts (25 ng) of
RNA from each fraction (input, supernatant and RIP; +/-
dox treated fractions). Equivalent amounts of cDNA
were then used for RT-PCR. Our results showed that P27
levels were barely detectable in the input fraction (I) but
enriched in the RIP fraction (Figure 2c). This indicates
that P27 mRNA is indeed pulled down specifically with
HA-DND1 in the RIP fraction (Figure 2c). Although P27
is barely detectable in the input lanes in Figure 2c, P27 is
normally present in the hES/HA-DND1 cells as it can be
detected in both untreated and dox-treated cells using
higher PCR cycles (Figure 2d).
In contrast, RT-PCR for HPRT indicated that it is pre-
sent in all the fractions in dox treated and untreated
cells. This rules out specific interaction of HPRT mRNA
with HA-DND1.
In addition, we monitored for the presence of HA-
DND1 in the different fractions. Immunoblotting using
anti-DND1 show that the HA-DND1 was present in the
dox treated ES cells and in the input (I) fraction, but
not in the supernatant (S) fraction (Figure 2e). This
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Page 6 of 10indicates that the majority of induced HA-DND1 in the
input (I) fraction was efficiently immunoprecipitated by
anti-HA antibody and pelleted in the RIP fraction.
Because of proteinase K digestion prior to RNA elution,
immunoblotting could not be performed on the RIP
fraction.
Pluripotency factors, tumor suppressors and apoptotic
factors are DND1 targets
Next, we examined whether transcripts of pluripotency
factors associate with DND1. This is because DND1 is
normally expressed in both ES cells and primordial germ
cells (PGCs) and both of these cell types express pluripo-
tency factors. Thus, we hypothesized that transcripts
encoding pluripotency factors may be targets of DND1 in
ES cells. Therefore, we performed RT-PCR on RIP frac-
tions to test for pull-down of mRNAs of candidate pluri-
potency factors such as OCT4, SOX2, NANOG, LIN28,
KLF4 and CMYC. We also examined whether the mRNA
transcripts of cell cycle regulators and tumor suppressors
(LATS2, TP53) and apoptotic factors (BAX, BCLX)a r e
targets of DND1.
The results from RIP-RT experiments showed that the
following pluripotency factors are specific targets of
DND1: OCT4, SOX2, NANOG and LIN28 (Figure 3b and
3c). In the case of OCT4, SOX2, NANOG (Figure 3b) we
observe specific pull down of the transcripts in lane 13
(anti-HA, dox +, RT +) compared to lane 14 (anti-HA,
dox -, RT +). In addition we observed enrichment of tran-
script compared to that in the Input (I) lane (lane 1). In
contrast, similar comparison of the transcript levels in the
test and control lanes with the input lanes (Figure 3c,
lanes 7, 8 and 1), lead us to conclude that KLF4 and C
MYC are not specific targets of DND1. We note that faint
bands are observed in the control RIP lanes (Figure 3c, d,
lanes 8 and 9). These bands indicate that anti-HA anti-
body (in -dox cells, lane 8) and anti-FLAG antibody
(in +dox cells, lane 9) can also pull down low levels of
transcripts, which represent non-specific interactions. In
comparison, specific pull-down of transcripts occurs
at higher levels (using anti-HA antibody in +dox cells,
lane 7).
TP53 and LATS2 are also specifically pulled down in
the RIP fraction of dox-treated cells (Figure 3c, compar-
ing lanes 7 and 8). However, in the case of TP53 and
LATS2, there was not significant enrichment in the RIP
fraction (Figure 3c, lane 7) compared to the input (I)
lane (Figure 3c, lane 1). This indicates that LIN28 is
more efficiently pulled down with DND1 compared to
TP53 and LATS2.
On the other hand, transcripts of both the pro-apopto-
tic factor BAX and the anti-apoptotic factor BCLX are
very efficiently pulled down with DND1 (Figure 3d).
There is also significant enrichment of BAX and BCLX
transcripts in the RIP fraction of dox treated cells (Figure
3d, comparing lanes 7 to 8 and 1).
DND1 binding sequences in the 3’-UTRs of mRNA
transcripts
Next, we examined whether the transcripts studied con-
tains the known DND1 binding sequences. We therefore
examined the full-length transcripts for U-rich DND1
interacting sequences that were previously mapped in the
3’-UTR of P27 [11] as well as for sequences that were
mapped to the 3’-UTR of Nanos1 and TDRD7.I nc a s e s
where multiple transcripts of a gene are known, all the
transcripts were examined for the presence of any of the
DND1 interacting sequence. We found that none of the
transcripts that we examined in this study contained the
same DND1 interacting sequence as P27. However, the
3’-UTRs of OCT4, NANOG, MYC and LIN28 harbored
sequences similar to the DND1 interacting sequences
found in TDRD7. LATS2 3’-UTRs contained the DND1
interacting sequences similar to that found in Nanos1
(Table 1).
Thus, sequence examination of transcripts alone does
not predict whether a particular transcript will bind to
and be pulled-down with DND1. Although MYC did not
bind to HA-DND1, the 3’-UTR of one of its transcripts
contains putative DND1 binding sequences. In contrast,
even though BAX and BCLX bound very efficiently to
DND1 ribonucleoprotein complex, we did not find
DND1 binding sites in any of its transcripts. This sug-
gests that there likely exists additional DND1 binding
sequences that are yet to be defined. To test this, we
aligned the 3’-UTRs of the DND1 interacting mRNAs to
examine for any common sequences. We found some
regions with weak consensus that may represent novel
DND1 binding sites. Further experimental analysis will
be required to establish whether these are indeed DND1
binding sites.
The other possibility is that interaction of mRNAs
with DND1 may be mediated through co-interaction of
DND1 with other proteins and thus presence of DND1
binding sequences within mRNAs may not be essential
for interaction.
Discussion
We demonstrate use of a stable, inducible ES cell line to
identify transcripts that associate with DND1. Our
results show that transcripts of pluripotency factors
associate with DND1. OCT4, SOX2 and NANOG are
key transcription factors essential for maintenance of
the pluripotent state of ES cells [39-41] and are also
important for early germ cells [3,22,24]. These results
lead us to hypothesize that DND1 likely imposes
another level of regulation of expression of pluripotency
factors. However, it remains to be determined how
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properties.
miRNAs target multiple mRNAs simultaneously. On
the other hand, DND1 is also able to inhibit miRNA
activity from multiple mRNAs [11,13]. Our results also
hint at the broad range of mRNA targets of DND1.
Further studies are needed to elucidate the role of DND1
in modulating specific miRNA activity from each mRNA.
Our RIP-RT results show that the transcripts of the
cell cycle regulators, TP53 and LATS2 mRNA are also
targets of DND1. This observation is corroborated by a
recent study where RIP technique was applied to
NIH3T3 cells and showed that tagged DND1 is able to
pull down a number of cell cycle regulators including
Lats2 and p53 [42].
In addition, mRNA transcripts of both the pro-apoptotic
factor BAX and the anti-apoptotic factor mRNA, BCLX,
are efficiently pulled down with DND1. Thus DND1 inter-
acts with a broad variety of targets and with mRNAs that
have opposite effects, as for example, DND1 associates
with mRNAs of both anti- and pro-apoptotic factor, BCLX
and BAX, respectively. This raises the question as to what
confers specificity for DND1 function? One possibility is
that there exist factors that favor interaction with specific
mRNAs at particular stages of the cell cycle or under cer-
tain physiological conditions. It is also likely that intrinsic
and cellular factors may regulate DND1 function to pro-
mote cell survival and maintain a pluripotent cell state.
Depending on the physiological state of the cell, the bal-
ance of expression of the opposing factors likely determine
cell fate, death or transformation.
Germ cells, testicular cancer cells and ES cells share
gene expression patterns [21,24,43]. For example, SOX2,
NANOG and LIN28 expression can be used to distin-
guish different histological subtypes of human testicular
cancers [44,45]. This is thought to reflect the origin of
testicular cancer from germ cells. Whether the same
pluripotency factors also associate with DND1 in germ
cells will have to be experimentally determined. Interest-
ingly, our observation that DND1 interacts with pluripo-
tency and anti-apoptotic factor mRNAs may explain
why lack of DND1 results in the death of germ cells in
mice. Pluripotency factors are able to reprogram differ-
entiated adult cell types into iPS (induced pluripotent
Table 1 Transcripts with potential DND1 binding sequences
Gene Number of transcripts
1 DND1 interacting sequence
2 Interaction with DND1
3
P27 (CDKN1B) 4 CDKN1B-001 (ENST00000228872)
1196- TTTTTCCTTATTT -1208
1236- TTTTTACCTTTT -1247
CDKN1B-002 (ENST00000442489)
537- TTTTTCCTTATTT -549
+
HPRT1 3 --
OCT4 (POU5F1) 6 POU5F1-001 (ENST00000434616)
1345- TTGATTTT -1352
POU5F1-002 (ENST00000412166)
1088- TTGATTTT -1095
POU5F1-004 (ENST00000463773)
621- TTGATTTT -628
+
SOX2 1 -+
NANOG 3 NANOG-001 (ENST00000229307)
2042- TTGATTTT -2049
+
LIN28 2 LIN28A-001 (ENST00000326279)
3879- TTGATTTT -3886
LIN28A-201 (ENST00000254231)
3326- TTGATTTT -3333
+
KLF4 7 --
MYC 5 MYC-001 (ENST00000377970)
2283-TTGATTTT -2290
-
TP53 15 -+
LATS2 3 LATS2-001 (ENST00000382592)
4176- TTTTATTTT -4184
+
BAX 12 -+
BCLX (BCL2L1) 10 -+
1 Number of expressed transcripts as reported in Ensembl (http://www.ensembl.org/Homo_sapiens/Info/Index), not including duplications
2 The specific transcript(s) that encodes previously described DND1 interacting sequences [11]. The nucleotide position of the DND1 interacting sequence within
the full-length transcript is indicated.
3 As experimentally determined and shown in Figure 2 and 3.
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Page 8 of 10stem) cells. For example, human iPS cells require OCT4,
SOX2, NANOG,a n dLIN28 whereas mouse iPS cells
require Oct4, Sox2, Myc and Klf4 [46,47]. Interestingly,
we found that transcripts encoding OCT4, SOX2,
NANOG and LIN28 but not KLF4 associate with DND1
in hES cells.
Surprisingly, we found that DND1 interacting sequence
similar to P27 are rarely present in other transcripts.
However, the 3’-UTR of some transcripts harboured
DND1 interacting sequences described in Nanos1 and
TDRD7. Therefore, at present, based on sequence analy-
sis alone, it is difficult to predict whether a particular
transcript interacts with DND1.
Conclusion
In conclusion, we report the generation of the inducible
hES cell system (hES/HA-DND1 cells) and demonstrate
the advantage of using this stable, dox inducible hES cell
system to identify the RNA targets of DND1. hES cells clo-
sely resemble primordial germ cells and we can induce
and control expression of modest levels of HA-tagged
DND1. Using the hES/HA-DND1 cells, we demonstrate
that transcripts of pluripotency factors, cell cycle regula-
tors and apoptotic factors are associated with DND1 and
are likely targets of regulation by DND1. We found that
RIP followed by RT-PCR allows us to quickly and readily
discriminate between specific and non-specific mRNA tar-
gets of DND1. Further techniques such as microarray or
RNA-Seq following RIP will be useful to identify the global
targets of DND1 from ES cells. Although a number of
transcripts associate with DND1, surprisingly, DND1
interacting sequence similar to P27 are rarely present in
other transcripts. Thus additional DND1 interacting
sequences remain to be identified.
Our result suggests that DND1 imposes another level
of translational regulation that may modulate expression
of critical factors in ES cells. Because DND1 is impli-
cated in reciprocally regulating miRNA mediated trans-
lation suppression of specific target mRNAs, this
suggests that the balance between DND1 and miRNAs
modulates context-dependent mRNA targets.
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